Table 1.

Currently Approved and Discontinued Biologics

Generic Name	Brand Name	Indications
Innate Immunity
Eculizumab	Soliris	Paroxysmal nocturnal hemoglobinuria
Anakinra	Kineret	Rheumatoid arthritis (RA) Neonatal Onset Multisystem Inflammatory Disease
Canakinumab	Ilaris	Familial cold autoinflammatory syndrome Muckle-Wells syndrome Systemic juvenile idiopathic arthritis (SJIA)
Rilonacept	Arcalyst	Cryopyrin associated periodic syndromes
Tocilizumab	Actemra	RA, SJIA, Polyarticular juvenile idiopathic arthritis
Adaptive Immunity
Secukinumab	Cosentyx	Plaque psoriasis, Psoriatic arthritis Ankylosing spondylitis
Ustekinumab	Stelara	Plaque psoriasis, Psoriatic arthritis
T cells
Basiliximab	Simulect	Renal transplant rejection
Abatacept	Orencia	RA, Juvenile idiopathic arthritis (JIA)
Belatacept	Nulojix	Renal transplant rejection
Ipilimumab	Yervoy	Melanoma, unresectable or metastatic; adjuvant
Adhesion Molecules
Natalizumab	Tysabri	Multiple sclerosis Ankylosing spondylitis Crohn’s disease (CD)
Vedolizumab	Entyvio	Inflammatory bowel disease (CD, ulcerative colitis)
B cells
Rituximab	Rituxan	RA Granulomatous polyangiitis, Microscopic polyangiitis
Belimumab	Benlysta	Systemic lupus erythematosus
Discontinued
Daclizumab		Renal transplant rejection
Efalizumab		Plaque psoriasis
Atacicept		Systemic lupus erythematosus